CTXR Stock Forecast: Citius Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Citius Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Citius Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (65): The business earns solid, repeatable profits on what it owns.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CTXR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTXR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 11 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 23 May 2025 | Maxim Group | Downgrade | Hold | — |
| 15 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 Dec 2024 | D. Boral Capital | Upgrade | Buy | — |
| 22 Nov 2024 | D. Boral Capital | Downgrade | Hold | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 19 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 8 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 15 July 2024 | EF Hutton | Initiates | Buy | — |
| 31 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTXR.
This page is one stock. Monday covers all of them.
CTXR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CTXR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Citius Pharmaceuticals, Inc. returned −48.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CTXR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.0×
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 49% of US stocks
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- −10.4%
- Earnings growth (YoY)
- —
- Gross margin
- 67.1%
- Operating margin
- —
- Net margin
- —
Higher than 16% of US stocks
Higher than 80% of US stocks
- Return on equity
- −81.1%
- Return on assets
- −26.6%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Citius Pharmaceuticals, Inc. has a market value of $14.0M and an enterprise value of $13.4M.
Revenue in the twelve months to 30 June 2026: $7.1M.
Net income over the same four quarters: −$58.2M, a −818.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$34.9M.
Citius Pharmaceuticals, Inc. employs 23 people — $309K of revenue per employee.
Data provided by Twelve Data
CTXR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CTXR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Citius Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CTXR
What is the CTXR stock price forecast for 2026-2027?
The median 12-month analyst price target for Citius Pharmaceuticals, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTXR stock a buy right now?
Of the 1 analyst covering Citius Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Pharmaceuticals, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTXR?
As at 21 Nov 2026, Citius Pharmaceuticals, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (65 of 100).
Will CTXR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $4, and Ticker Nerd's factor model ranks Citius Pharmaceuticals, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTXR stock forecast for 2030?
No analyst covering Citius Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has CTXR stock performed over the past year?
Citius Pharmaceuticals, Inc. returned -48.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Citius Pharmaceuticals, Inc. do?
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.
CEO Mr. Leonard L. Mazur · 23 employees · United States · https://citiuspharma.com